MagForce Nanotechnologies
AG (FWB:MF6) has successfully completed patient recruitment for its study
on recurrent glioblastoma, which is of critical importance for demonstrating
the efficacy of its proprietary Nano-Cancer® therapy. The results of this
phase II clinical trial will serve as the basis for the conformity evaluation
procedure required under the German Medical Devices Act (Medizinproduktegesetz).
“The completion of patient recruitment is a further milestone on the
way to receiving CE European conformity marking for the therapeutic procedure
we have developed through which tumors can be specifically and accurately heated
and destroyed from the inside out. We plan on preparing the statistical data
in the fourth quarter of 2009, as soon as enough patients have concluded the
post-observation period or have otherwise reached the study endpoint, so that
we will be able to have the product file put together before the end of this
year. Once we have received the CE marking, which certifies conformity with
health and safety regulations throughout the European Economic Area, we hope
to be in a position already next year to commence marketing of Nano-Cancer®
therapy throughout Europe,” said Dr. Uwe Maschek, CEO of MagForce Nanotechnologies
AG.
MagForce Nanotechnologies AG is the world’s leading company in the area
of nanotechnology-based cancer treatment. Its patented Nano-Cancer® therapy
allows the targeted destruction of tumors using superparamagnetic nanoparticles
to generate heat. The nanotechnology from MagForce represents a revolutionary
approach to the future successful treatment of solid tumors.
Posted September 22nd, 2009
